<DOC>
	<DOC>NCT01666782</DOC>
	<brief_summary>The safety and immunogenicity of high dose influenza vaccine has not been studied in young patients receiving chemotherapy. This study will evaluate and compare the immunogenicity and safety of high dose influenza to standard dose influenza vaccine in adult oncology patients who are younger than 65 years old receiving chemotherapy.</brief_summary>
	<brief_title>Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1. 18 years old to less than 65 years old 2. Subjects with malignancy must be receiving chemotherapy 3. Medically stable 4. Able to understand and willingness to sign a written informed consent 5. Able to comply with study procedures 6. Life expectancy of more than 3 months 7. Adequate organ function: ANC &gt;1000/mm3 Platelet &gt;100,000/uL Creatinine &lt;2 mg/dL AST and ALT &lt;3 times the ULN 1. Allergy to eggs 2. Prior allergy to Influenza Vaccine 3. History of GuillainBarre Syndrome 4. Current febrile illness 5. Other immunosuppressive disease (recipients of solid organ transplant, uncontrolled HIV) 6. Autologous or Allogenic Stem Cell Transplant with in a year 7. Current immunotherapy or immunochemotherapy in the last 6 months (rituximab or ofatumumab)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Influenza vaccine</keyword>
	<keyword>Oncology</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>